T-Therapeutics has raised $133 million in a funding round focused on bispecific antibodies, aiming to expand its platform for cancer targets that are difficult to drug and for selective autoimmune treatments. The company’s strategy emphasizes engineering that it claims can improve access to known but “undruggable” biology. The financing signals renewed investor appetite for modality-heavy companies where platform differentiation is central to the value proposition. For the biotech sector, it also highlights how bispecifics remain a core financing theme, particularly when startups can tie their molecule designs to clear clinical hypotheses. While the article does not detail a specific lead candidate or trial readout, the size of the round suggests T-Therapeutics is looking to accelerate discovery-to-clinic timelines and build out its preclinical portfolio. Investors will likely watch how the company converts its claimed selectivity and target reach into IND-enabling progress and early clinical proof points.